Please Wait
Applying Filters...

Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

Update your Virtual Booth on PharmaCompass, ask us

About

At TOLREMO, we address non-genetic cancer drug resistance to transform targeted treatment regimens into long-term therapeutic solutions. By targeting early transcriptional reprogramming, cancer's first defense to targeted treatments, our goal is to prevent therapy evasion before it occurs. We are advancing our lead compound as a critical component of success for a wide range of targeted treatment regimens, including the curren...
At TOLREMO, we address non-genetic cancer drug resistance to transform targeted treatment regimens into long-term therapeutic solutions. By targeting early transcriptional reprogramming, cancer's first defense to targeted treatments, our goal is to prevent therapy evasion before it occurs. We are advancing our lead compound as a critical component of success for a wide range of targeted treatment regimens, including the current standard of care as well as future cancer therapies.

List your booth number for exhibitions, ask us